Indonesia and Russia are in discussions to collaborate on pharmaceutical technology transfers, aiming to bolster Indonesia’s domestic medicine production and reduce its reliance on imports. This potential partnership was explored in a meeting between Indonesia’s Food and Drug Authority (BPOM), led by Taruna Ikrar, and Russian Deputy Minister of Industry and Trade Alexey Vladimirovich Gruzdev.
The talks focused on enhancing pharmaceutical manufacturing capabilities, improving quality inspections, and employing digital technologies to ensure product safety and traceability. A key goal for Indonesia is to expand local production of essential healthcare products, particularly diabetes treatments like insulin and glucagon-like peptide-1 (GLP-1) medicines. Other areas of interest include cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products.
Russian companies have shown interest in transferring technology and possibly setting up manufacturing facilities in Indonesia, with a focus on producing insulin, oncology medicines, and biotechnology products. Several Russian pharmaceutical firms have already submitted product registration documents to BPOM, indicating a readiness to engage further in this collaboration.
The two nations also reviewed their existing cooperation frameworks, including Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. Discussions are ongoing to finalize a memorandum of understanding that would establish a more robust framework for collaboration. Russia has proposed exploring mutual recognition of GMP certificates to streamline regulatory procedures and improve market access in both countries, although this requires further discussions to ensure regulatory compatibility.
To enhance Indonesia’s inspection capabilities, Russia has offered technical training, including virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. Talks also covered the integration of digital regulatory systems and supply-chain monitoring, with both sides expressing a keen interest in continuing negotiations and expanding the scope of their cooperation through future meetings and visits to pharmaceutical manufacturing facilities.